1 XERIS BIOPHARMA HOLDINGS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”) has adopted this Amended and Restated Non-Employee Director Compensation Policy (as may be amended, restated or otherwise modified from time to time, this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board. Applicable Persons This Policy shall apply to each director of the Company’s Board who is not an employee of the Company or any of its subsidiaries. Cash Retainers Annual Retainer for Board Membership: $50,000 for general availability and participation in meetings and conference calls of our Board, to be paid quarterly in arrears, pro- rated based on the number of actual days served by the director during such calendar quarter. Additional Annual Retainer for Non-Executive Chair of the Board: $45,000 Additional Annual Retainer for Lead In

…

NOTICE OF RESTRICTED STOCK UNIT GRANT UNDER THE

REVELATION BIOSCIENCES, INC. 2026 EQUITY Inducement PLAN

Revelation Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to the Revelation Biosciences, Inc. 2026 Equity Inducement Plan (as may be amended from time to time, the “Plan”), hereby grants to the individual named below (the “Participant”) the number of Restricted Stock Units (as defined in the Plan) set forth below (the “Restricted Stock Units”). The Restricted Stock Units are subject to all of the terms and conditions set forth in this Notice of Restricted Stock Unit Grant (this “Grant Notice”), in the Restricted Stock Unit Award Agreement attached hereto (the “Award Agreement”), and in the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein will have the meaning set forth in the Plan. This Restricted Stock Units grant has been made as of the grant date indicated below, which shall be referred to as the “Grant Date.”

Participant:___________________________

…

June 12, 2026

Dear John:

As you are aware, Payoneer Global Inc. (the “Company”) entered into that certain Agreement and Plan of Merger, dated as of June 12, 2026 (the “Merger Agreement”), by and among the Company, Neon Maple Parent Inc. (“Neptune”) and Panda Acquisition Sub Inc. (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving the Merger, and the Company’s common stock will no longer be publicly traded (collectively, the “Transactions”).  

This letter agreement (this “Letter Agreement”) sets forth our mutual understanding and agreement regarding: (i) the impact of the Transactions on your ability to claim a resignation of employment due to Good Reason under the terms of your Employment Agreement (as defined below); and (ii) your continued provision of services to Neptune and its affiliates for at least nine months following the closing of the Transactions (the “Closing”).

…

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

PROMISSORY NOTE

Dated as of June 4, 2026

Principal Amount: Up to $100,000.00

…

B. RILEY FINANCIAL, INC.
2021 STOCK INCENTIVE PLAN

SPECIAL RESTRICTED STOCK UNIT AWARD AGREEMENT

This Special Restricted Stock Unit Award Agreement (this “Award Agreement”) evidences a special award of time-based restricted stock units (“RSUs”) by BRC Group Holdings, Inc., (f/k/a B. Riley Financial, Inc.) a Delaware corporation (together with any Subsidiary, and any successor entity thereto, the “Company”), under the B. Riley Financial, Inc. 2021 Stock Incentive Plan (as amended, supplemented or modified from time to time, the “Plan”). Capitalized terms not defined in this Award Agreement have the meanings given to them in the Plan.

…

[Execution Copy]

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into by and between BRC Group Holdings, Inc. (the “Company”) and Fred Knopf (“Executive”), effective as of July 1, 2026 (“Effective Date”).

WHEREAS, the Company desires to retain the services of Executive, and Executive desires to be employed by the Company.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the Company and Executive, intending to be legally bound, hereby agree as follows:

AGREEMENT

…

Exhibit 10.4 Execution Version

FIRST AMENDMENT TO CREDIT AGREEMENT, LIMITEDWAIVER, AND OMNIBUS JOINDER AGREEMENT

This FIRST AMENDMENT TO CREDIT AGREEMENT, LIMITED WAIVER, AND

OMNIBUS JOINDER AGREEMENT (as the same may be amended, supplemented, restated or otherwise modified from time to time, this “Agreement”) is entered into as of June 30, 2026 (the “First Amendment Effective Date”), by and among (1) TARGUS INTERNATIONAL LLC, a Delaware limited liability company (“Targus International”), TARGUS US LLC, a Delaware limited liability company (“Targus US”), HYPER PRODUCTS INC., a Delaware corporation (“Hyper Products”), TARGUS (CANADA) LTD., a corporation organized under the federal laws of Canada (together with Targus International, Targus US, and Hyper Products, each a “Borrower” and collectively, the “Borrowers”), (2) TIGER US HOLDINGS INC., a Delaware corporation (“Parent”), TARGUS US NEWCO INC., a Delaware corporation (“NewCo”), TARGUS SPAIN S.L, a Spanish limited liability company, incorporated in Spain and filed at the Trade Registry of Madrid under Volume 39209, Folio 48, reg

…

Permian Resources Corporation

2026 Non-Employee Director Compensation Program

Effective Date: August 4, 2026

Each member of the Board of Directors (the “Board”) of Permian Resources Corporation (the “Company”) who is not an employee of the Company or any parent or subsidiary of the Company (each, a “ Non-Employee Director”) will receive the compensation in this Permian Resources Corporation 2026 Non-Employee Director Compensation Program (this “Program”) of the Company for service as a Non-Employee Director. The compensation described in this Program will be paid or be made, as applicable, automatically and without further action of the Board to each Non-Employee Director who is entitled to receive the compensation, unless the Non-Employee Director declines receipt of the compensation by written notice to the Company prior to the payment thereof. The terms and conditions of this Program will supersede any prior cash or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors. This Program will become effective

…

PERMIAN RESOURCES CORPORATION
FOURTH AMENDED AND RESTATED SEVERANCE PLAN

I. PURPOSE

The purpose of this Permian Resources Corporation Fourth Amended and Restated Severance Plan (the “Plan”) is to encourage employees of Permian Resources Corporation (together with any successor, the “Company”) and its subsidiaries to remain in the employ of the Employer by providing, among other things, severance protections to such employees in the event their employment is terminated under the circumstances described in this Plan. This Plan supersedes, and amends and restates in its entirety, the Permian Resources Corporation Third Amended and Restated Severance Plan, as amended to date.

II. DEFINITIONS

For purposes of this Plan, the following terms shall have the meanings set forth below:

A. “Administrator” means the Committee or any other committee designated by the Board to administer the Plan.

…

LEASE TERMINATION AGREEMENT

This Lease Termination Agreement (this "Agreement"), dated as of April 1, 2026, is entered into by and between MIT 130 BROOKLINE LEASEHOLD LLC, a Massachusetts limited liability company with an address c/o MIT Cambridge Real Estate LLC, One Broadway, Suite 09-200, Cambridge, MA 02142 ("Landlord"), and INTELLIA THERAPEUTICS, INC., a Delaware corporation with an address of 40 Erie Street, Cambridge, MA 02139 ("Tenant").

WHEREAS, Landlord and Tenant are the current parties to that certain Lease dated October 21, 2014, as amended by that certain First Amendment to Lease dated as of April 5, 2019, and as further amended by that certain Second Amendment to Lease (the “Second Amendment”) dated as of March 12, 2020 (collectively, the "Lease") for premises consisting of approximately 15,169 rentablesquare feet of space (as more particularly described in the Lease, the "Premises") in the building located at 130 Brookline Street, Cambridge, Massachusetts (the "Building");

WHEREAS, the Lease is scheduled to expire on May 31, 2031;

…

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) may be competitively harmful if publicly disclosed.

Amendment No. 4

to the

Collaboration and License Agreement

This Amendment No. 4 (“Amendment”) to the Collaboration and License Agreement effective November 16, 2022 as amended by Amendment No. 1 effective June 28, 2024, Amendment No. 2 effective October 7, 2025, and Amendment No. 3 effective May 16, 2026 (collectively the “Agreement”) by and between CytomX Therapeutics, Inc., having an address at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, U.S.A. (“CytomX”), and Regeneron Pharmaceuticals, Inc., a New York company with a business address located at 777 Old Saw Mill River Road, Tarrytown, NY 10591, U.S.A. (“Regeneron”) shall be effective as of May 31, 2026 (“Amendment No. 4 Effective Date”) IF DOCVARIABLE main_contracting_party_type \* CHARFORMAT Legal entity = "Physical person" " DOCVARIABLE main_contracting_party_title \* CHARFORMAT Contracting Party Title DOCVARIABLE main_contra

…

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) may be competitively harmful if publicly disclosed.

AmendmentNo.3 to the

CollaborationandLicenseAgreement

This Amendment No. 3(“Amendment”) totheCollaborationandLicense Agreement effectiveNovember 16,2022asamendedbyAmendmentNo.1effectiveJune28,2024andAmendmentNo.2effectiveOctober 7, 2025 (collectively the “Agreement”) by and between CytomX Therapeutics, Inc., having an address at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, U.S.A. (“CytomX”), and Regeneron Pharmaceuticals, Inc., a New York company with a business address located at 777 Old Saw Mill River Road, Tarrytown, NY 10591, U.S.A. (“Regeneron”) shall be effective as of May 16, 2026 (“Amendment No. 3 Effective Date”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

WHEREAS, Regeneron and CytomX wish to extend the period within which Regeneron may nominate certain Collaboration Programs;

…